Skip to main content
Article thumbnail
Location of Repository

High dose chemotherapy in breast cancer reviewed

By J.W. Baars, S. Rodenhuis, E. van der Wall and J.H. Schornagel

Abstract

Laboratory and experimental data show a dose response curve\ud for cytostatic drugs, especially for alkylating agents. For many\ud malignancies, clinical evidence of a dose response relationship\ud is limited.\ud The dose limiting toxicity of most cytostatic drugs is myelosuppression,\ud which can be circumvented by the use of haematopoietic\ud growth factors and/or autologous hone marrow or\ud peripheral stem cell support. Clinical data derived from studies in patients with metastatic\ud breast cancer, show that dose escalations of 1.5-2 x standard\ud dosages, possible without autologous bone marrow or peripheral\ud stem cell transport can induce higher remission rates,\ud which did not, however, correspond to a significant survival\ud advantage. Despite promising results from small trials with\ud high dose intensity treatment in combination with peripheral\ud stem cell or bone marrow support (depending on the schedule\ud used, dose escalations possible of 5-10 x the standard dosages)\ud in a selected patient population with high risk or metastatic\ud breast cancer, they do not justify the use of this approach outside\ud the setting of clinical studies. We have to gain more\ud knowledge of selecting the patients who are likely to profit\ud from high dose chemotherapy as well as to continue focusing\ud on improvement of efficacy, reduction of the considerable\ud morbidity and costs of this treatment

Topics: Geneeskunde, breast cancer, high dose chemotherapy, peripheral stem cell transplantation, autologous bone marrow transplantation, haematopoietic growth factors
Year: 1995
OAI identifier: oai:dspace.library.uu.nl:1874/23082
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dspace.library.uu.nl:80... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.